 Home > Active Ingredient News > Immunology News > A&R: A Safety and Efficacy Study of Bimegizumab in Active Psoriatic Arthritis

A&R: A Safety and Efficacy Study of Bimegizumab in Active Psoriatic Arthritis

 Last Update: 2022-08-15
 Source: Internet
 Author: User

Tags

safety industrial supplies

1 0 copper

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

OBJECTIVE: To evaluate the long-term safety, tolerability, and efficacy of bimegizumab in the treatment of active psoriatic arthritis (PsA.

Long-term safety, tolerability, and efficacy of bimegizumab in psoriatic arthritis (PsA )

METHODS: Adult patients with active PsA who completed the double-blind and dose-blind phases of the BE-active randomized controlled trial could enroll in an open-label extension (OLE) study at week 48 , after which patients received 160 mg of bimegizumab every four wee.

Open Label Extensions (OLE) Research Open Label Extensions (OLE) Research

RESULTS: At Week 152, 161/206 patients (72%) remained in the stu.

Efficacy at 48 weeks was maintained in O.

100% skin clearance with minimal disease activity

Conclusions: The safety profile of bimegizumab was consistent with previous reports , and no new safety signals were identified

Bimegizumab safety profile consistent with previous reports No new safety signals identified

Source:

Coates LC, McInnes IB, Merola JF, et .

Coates LC, McInnes IB, Merola JF, et .
Safety and Efficacy of Bimekizumab in Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 2b Randomized Controlled Trial and its Open-Label Extension Study [published online ahead of print, 2022 Jul 1
Arthritis Rheumat.
2022;11002/a.
4228 doi:11002/a.
42280 Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.